Soluble ST2 as a prognostic marker in community-acquired pneumonia

作者: Masato Watanabe , Hajime Takizawa , Masaki Tamura , Akira Nakajima , Daisuke Kurai

DOI: 10.1016/J.JINF.2015.02.004

关键词: C-reactive proteinImmunologyInternal medicineArea under the curveUnivariate analysisHazard ratioCommunity-acquired pneumoniaPneumonia severity indexMedicineBiomarker (medicine)PneumoniaGastroenterology

摘要: Summary Objectives Community-acquired pneumonia (CAP) is associated with high mortality when initial treatment fails. Early identification of these patients allows physicians to modify treatments earlier, increasing survival. Methods Ninety-one hospitalized CAP were studied. Serum soluble ST2 levels measured at diagnosis and 3, 7, 14 days (days 0, 14) after the initiation antimicrobial treatment. The predictive value all-cause in-hospital additive effect on severity index (PSI) evaluated. Results In univariate analysis, serum death (hazard ratios: 3.1, 10.0, 12.0, 22.6, respectively). multivariate a combination day 3 (above 2700 pg/ml) PSI higher accuracy than alone (net reclassification improvement, 0.44; integrated discrimination 0.17; P  = 0.001 for both). Specifically, simultaneous presence (day 3) 5 was suggestive risk (mortality 78% vs. 39%, Conclusions Soluble prognostic indicator can add of the PSI.

参考文章(35)
H Yin, XY Li, BH Yuan, BB Zhang, SL Hu, HB Gu, XB Jin, JY Zhu, None, Adenovirus-mediated overexpression of soluble ST2 provides a protective effect on lipopolysaccharide-induced acute lung injury in mice. Clinical and Experimental Immunology. ,vol. 164, pp. 248- 255 ,(2011) , 10.1111/J.1365-2249.2011.04326.X
Roman Klemenz, Jacqueline Gheyselinck, Hans Reimer Rodewald, Dirk R. Moritz, Dirk R. Moritz, The IL-1 Receptor-Related T1 Antigen Is Expressed on Immature and Mature Mast Cells and on Fetal Blood Mast Cell Progenitors Journal of Immunology. ,vol. 161, pp. 4866- 4874 ,(1998)
FRANCISCO ARANCIBIA, SANTIAGO EWIG, JOSE ANTONIO MARTINEZ, MAURICIO RUIZ, TORSTEN BAUER, MARIA ANGELES MARCOS, JOSEP MENSA, ANTONI TORRES, Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. American Journal of Respiratory and Critical Care Medicine. ,vol. 162, pp. 154- 160 ,(2000) , 10.1164/AJRCCM.162.1.9907023
Damo Xu, Woon Ling Chan, Bernard P. Leung, Fang-ping Huang, Rachel Wheeler, David Piedrafita, John H. Robinson, Foo Y. Liew, Selective Expression of a Stable Cell Surface Molecule on Type 2 but Not Type 1 Helper T Cells Journal of Experimental Medicine. ,vol. 187, pp. 787- 794 ,(1998) , 10.1084/JEM.187.5.787
Abelardo Martinez-Rumayor, Carlos A. Camargo, Sandy M. Green, Aaron L. Baggish, Michelle O’Donoghue, James L. Januzzi, Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. American Journal of Clinical Pathology. ,vol. 130, pp. 578- 584 ,(2008) , 10.1309/WMG2BFRC97MKKQKP
Beatriz Rosón, Jordi Carratalà, Núria Fernández-Sabé, Fe Tubau, Frederic Manresa, Francesc Gudiol, Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia Archives of Internal Medicine. ,vol. 164, pp. 502- 508 ,(2004) , 10.1001/ARCHINTE.164.5.502
Elizabeth K Brint, Damo Xu, Haiying Liu, Aisling Dunne, Andrew N J McKenzie, Luke A J O'Neill, Foo Y Liew, ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance Nature Immunology. ,vol. 5, pp. 373- 379 ,(2004) , 10.1038/NI1050
Hiroko Hayakawa, Morisada Hayakawa, Akihiro Kume, Shin-ichi Tominaga, Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation Journal of Biological Chemistry. ,vol. 282, pp. 26369- 26380 ,(2007) , 10.1074/JBC.M704916200
Mark T. Vander Lugt, Thomas M. Braun, Samir Hanash, Jerome Ritz, Vincent T. Ho, Joseph H. Antin, Qing Zhang, Chee-Hong Wong, Hong Wang, Alice Chin, Aurélie Gomez, Andrew C. Harris, John E. Levine, Sung W. Choi, Daniel Couriel, Pavan Reddy, James L.M. Ferrara, Sophie Paczesny, ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death The New England Journal of Medicine. ,vol. 369, pp. 529- 539 ,(2013) , 10.1056/NEJMOA1213299